New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
07:35 EDTFLDMFluidigm acquisition positive, says Oppenheimer
After Fluidigm agreed to buy DVS Sciences, Oppenheimer expects existing high customer overlap between the companies to accelerate product integration and sales synergies between them. The firm believes that DVS' CyTOF single-cell analysis system has certain advantages over traditional flow cytometry systems. It keeps an Outperform rating on Fluidigm.
News For FLDM From The Last 14 Days
Check below for free stories on FLDM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
07:04 EDTFLDMFluidigm upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Fluidigm to Outperform citing reasonable consensus revenue estimates and strong demand for single cell gene expression analysis tools. The firm has a $52 price target for shares.
April 9, 2014
08:24 EDTFLDMPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
April 7, 2014
07:44 EDTFLDMMarketo to hold a summit
Subscribe for More Information
April 2, 2014
09:01 EDTFLDMLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use